Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer

Volumn 15, Issue 3, 2017, Pages 384-390.e3

  Penttilä, Patrick ^a   Rautiola, Juhana ^a   Poussa, Tuija ^b   Peltola, Katriina ^a   Bono, Petri ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NOKIA RESEARCH CENTER   (United States)

Author keywords

Angiogenesis; Angiotensin system inhibitors; Hypertension; Renal cancer; Tyrosine kinase inhibitors

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; PAZOPANIB; SUNITINIB; ANGIOGENESIS INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; CHEMICALLY INDUCED; KIDNEY TUMOR; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RENAL CELL CARCINOMA; VERY ELDERLY; YOUNG ADULT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYPERTENSION; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RETROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85009830115     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2016.12.016     Document Type: Article

References (28)

1. Rixe, O., Billemont, B., Izzedine, H., Hypertension as a predictive factor of sunitinib activity. Ann Oncol, 18, 2007, 1117.
2. Rini, B.I., Cohen, D.P., Lu, D.R., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103 (2011), 763–773.
3. Rini, B.I., Schiller, J.H., Fruehauf, J.P., et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 17 (2011), 3841–3849.
4. Li, Y., Li, S., Zhu, Y., et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 16 (2014), 177–185.
5. Bono, P., Rautiola, J., Utriainen, T., Joensuu, H., Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 50 (2011), 569–573.
6. Wei, W., Jin, H., Chen, Z.W., Zioncheck, T.F., Yim, A.P., He, G.W., Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants. J Cardiovasc Pharmacol 44 (2004), 615–621.
7. Yang, R., Thomas, G.R., Bunting, S., et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27 (1996), 838–844.
8. Steeghs, N., Gelderblom, H., Roodt, J.O., et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 14 (2008), 3470–3476.
9. Dechend, R., Luft, F.C., Angiogenesis factors and preeclampsia. Nat Med 14 (2008), 1187–1188.
10. Chow, W.H., Dong, L.M., Devesa, S.S., Epidemiology and risk factors for kidney cancer. Nat Rev Urol 7 (2010), 245–257.
11. Haggstrom, C., Rapp, K., Stocks, T., et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One, 8, 2013, e57475.
12. Izzedine, H., Derosa, L., Le Teuff, G., Albiges, L., Escudier, B., Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol 26 (2015), 1128–1133.
13. Egami, K., Murohara, T., Shimada, T., et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112 (2003), 67–75.
14. Noguchi, R., Yoshiji, H., Ikenaka, Y., et al. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol Rep 22 (2009), 355–360.
15. Noguchi, R., Yoshiji, H., Kuriyama, S., et al. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9 (2003), 6038–6045.
16. Yoshiji, H., Kuriyama, S., Noguchi, R., Fukui, H., Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets 4 (2004), 555–567.
17. Dolley-Hitze, T., Jouan, F., Martin, B., et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?. Br J Cancer 103 (2010), 1698–1705.
18. Keizman, D., Huang, P., Eisenberger, M.A., et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 47 (2011), 1955–1961.
19. McKay, R.R., Rodriguez, G.E., Lin, X., et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 21 (2015), 2471–2479.
20. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000), 205–216.
21. Trotti, A., Colevas, A., Setser, A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003), 176–181.
22. Heng, D.Y.C., Xie, W., Regan, M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. J Clin Oncol 27 (2009), 5794–5799.
23. Deshayes, F., Nahmias, C., Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metabol 16 (2005), 293–299.
24. Rosenthal, T., Gavras, I., Angiotensin inhibition and malignancies: a review. J Hum Hypertens 23 (2009), 623–635.
25. Miyajima, A., Kosaka, T., Asano, T., et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62 (2002), 4176–4179.
26. Verhoest, G., Dolley-Hitze, T., Jouan, F., et al. Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma. Biomed Res Int, 2014, 2014, 901371.
27. Arafat, H.A., Gong, Q., Chipitsyna, G., Rizvi, A., Saa, C.T., Yeo, C.J., Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204 (2007), 996–1005 discussion: 1005-6.
28. Yoshiji, H., Noguchi, R., Ikenaka, Y., Kaji, K., Aihara, Y., Fukui, H., Impact of renin-angiotensin system in hepatocellular carcinoma. Curr Cancer Drug Targets 11 (2011), 431–441.